Data from a phase II study shows that AMGN's obesity drug MariTide leads to sustainable weight loss, robust improvements in cardiometabolic parameters and strong HbA1c reduction.

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

A new experimental weight loss drug from Amgen — the first in a growing group of drugs aimed at once-a-month injections instead of once a week — helped patients lose up to 20% of their weight in one ...

Mizuho Securities analyst Salim Syed has maintained their neutral stance on AMGN stock, giving a Hold rating yesterday.Don't Miss our Black ...

Study subjects taking the company’s MariTide lost about 20% of their weight in the 52-week trial.

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

The White House said it's moving to make the federal health insurance plans pay for anti-obesity drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound for people who are obese, even if they don ...

Here are six recent GLP-1 studies: 1. The use of Ozempic and Wegovy reduced healthcare costs for overweight or obese patients with heart failure or atherosclerotic cardiovascular disease, according to ...

Shares of weight-loss drugmakers Novo Nordisk and Eli Lilly rose on Tuesday after U.S. President Joe Biden proposed expanding ...

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...

Amgen Obesity Drug Cut Weight In Closely Watched Study Study subjects taking the company's MariTide lost about 20% of their weight in the 52-week trial. Novo Nordisk Says White House Obesity Plan Is ...